Last 12 months
Inside the activity.
0 purchase rows · 4 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 2 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
GrantPerformance Shares · Derivative | 3,553 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · derivative · entry 18 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,877 Underlying: Common Stock, $0.10 par value · 3,553 shares Expires 2014-03-31 F13 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. F14 · shares: Represents performance shares earned under the 2011-2013 Long-Term Performance Award. F13 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. F13 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
Exercise / conversionPerformance Shares · Derivative | 9,902 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · derivative · entry 17 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 9,902 shares Expires 2013-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F1 · shares: Represents distribution of performance shares earned under the 2010-2012 Long-Term Performance Award. F9 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F9 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
OtherPerformance Shares · Derivative | 377.8048 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · derivative · entry 16 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,902 Underlying: Common Stock, $0.10 par value · 377.8048 shares Expires 2013-03-31 F11 · derivative.exercise_price: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2013. F12 · shares: Represents dividend equivalents earned under the 2010-2012 Long-Term Performance Award. F11 · derivative.exercise_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2013. F11 · derivative.expiration_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2013. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
GrantPerformance Shares · Derivative | 2,879 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · derivative · entry 15 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,524.1952 Underlying: Common Stock, $0.10 par value · 2,879 shares Expires 2013-03-31 F9 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F10 · shares: Represents performance shares earned under the 2010-2012 Long-Term Performance Award. F9 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F9 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
Exercise / conversionMarket Share Units · Derivative | 2,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · derivative · entry 14 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,667 Underlying: Common Stock, $0.10 par value · 2,889 shares Expires 2016-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F2 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 6, 2012. The balance of the award is scheduled to vest in three equal installments on the second, third, and fourth anniversaries of the grant date. F2 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 6, 2012. The balance of the award is scheduled to vest in three equal installments on the second, third, and fourth anniversaries of the grant date. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
Exercise / conversionMarket Share Units · Derivative | 1,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · derivative · entry 13 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,197 Underlying: Common Stock, $0.10 par value · 1,197 shares Expires 2014-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F4 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 2, 2010. The balance of the award is scheduled to vest on the fourth anniversary of the grant date. F4 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 2, 2010. The balance of the award is scheduled to vest on the fourth anniversary of the grant date. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
Exercise / conversionMarket Share Units · Derivative | 1,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · derivative · entry 12 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,988 Underlying: Common Stock, $0.10 par value · 1,494 shares Expires 2015-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F3 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 1, 2011. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date. F3 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 1, 2011. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
Tax withholdingCommon Stock, $0.10 par value | 4,278 | $37.53 | $160,553.34 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 11 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,169.018 F7 · shares: Shares withheld for payment of taxes upon distribution of the 2010-2012 Long-Term Performance Award. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
Tax withholdingCommon Stock, $0.10 par value | 1,225 | $37.53 | $45,974.25 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 10 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,447.018 F6 · shares: Shares withheld for payment of taxes upon vesting of market share units. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
Tax withholdingCommon Stock, $0.10 par value | 802 | $37.53 | $30,099.06 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 9 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,672.018 F6 · shares: Shares withheld for payment of taxes upon vesting of market share units. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
Tax withholdingCommon Stock, $0.10 par value | 667 | $37.53 | $25,032.51 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 8 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,474.018 F6 · shares: Shares withheld for payment of taxes upon vesting of market share units. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
OtherCommon Stock, $0.10 par value | 399 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 7 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,141.018 F5 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
OtherCommon Stock, $0.10 par value | 591 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 6 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,742.018 F5 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
OtherCommon Stock, $0.10 par value | 658 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 5 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,151.018 F5 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
Exercise / conversionCommon Stock, $0.10 par value | 1,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 4 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,493.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents vesting of one-quarter of market share units granted on March 2, 2010. The balance of the award is scheduled to vest on the fourth anniversary of the grant date. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
Exercise / conversionCommon Stock, $0.10 par value | 1,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 3 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,296.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents vesting of one-quarter of market share units granted on March 1, 2011. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
Exercise / conversionCommon Stock, $0.10 par value | 2,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 2 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,802.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents vesting of one-quarter of market share units granted on March 6, 2012. The balance of the award is scheduled to vest in three equal installments on the second, third, and fourth anniversaries of the grant date. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
Exercise / conversionCommon Stock, $0.10 par value | 9,902 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 1 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,913.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents distribution of performance shares earned under the 2010-2012 Long-Term Performance Award. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
OtherPerformance Shares · Derivative | 844.848 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007238 · doc4.xml · derivative · entry 25 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,010.848 Underlying: Common Stock, $0.10 par value · 844.848 shares Expires 2015-03-31 F21 · derivative.exercise_price: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2015. F22 · shares: Represents dividend equivalents earned under the 2012-2014 Long-Term Performance Award. F21 · derivative.exercise_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2015. F21 · derivative.expiration_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2015. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
GrantPerformance Shares · Derivative | 21,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007238 · doc4.xml · derivative · entry 24 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,166 Underlying: Common Stock, $0.10 par value · 21,166 shares Expires 2015-03-31 F19 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2015. F20 · shares: Represents performance shares earned under the 2012-2014 Long-Term Performance Award. F19 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2015. F19 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2015. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
OtherPerformance Shares · Derivative | 2,465.8489 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007238 · doc4.xml · derivative · entry 23 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,242.8489 Underlying: Common Stock, $0.10 par value · 2,465.8489 shares Expires 2014-03-31 F17 · derivative.exercise_price: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2014. F18 · shares: Represents dividend equivalents earned under the 2011-2013 Long-Term Performance Award. F17 · derivative.exercise_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2014. F17 · derivative.expiration_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2014. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
GrantPerformance Shares · Derivative | 27,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007238 · doc4.xml · derivative · entry 22 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,777 Underlying: Common Stock, $0.10 par value · 27,866 shares Expires 2014-03-31 F15 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. F16 · shares: Represents performance shares earned under the 2011-2013 Long-Term Performance Award. F15 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. F15 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
Exercise / conversionPerformance Shares · Derivative | 99,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007238 · doc4.xml · derivative · entry 21 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 99,812 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F1 · shares: Represents distribution of performance shares earned under the 2010-2012 Long-Term Performance Award. F11 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F11 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
OtherPerformance Shares · Derivative | 3,832.0423 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007238 · doc4.xml · derivative · entry 20 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,812 Underlying: Common Stock, $0.10 par value · 3,832.0423 shares Expires not disclosed F13 · derivative.exercise_price: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2013. F14 · shares: Represents dividend equivalents earned under the 2010-2012 Long-Term Performance Award. F13 · derivative.exercise_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2013. F13 · derivative.expiration_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2013. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
GrantPerformance Shares · Derivative | 29,007 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007238 · doc4.xml · derivative · entry 19 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,979.9577 Underlying: Common Stock, $0.10 par value · 29,007 shares Expires not disclosed F11 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F12 · shares: Represents performance shares earned under the 2010-2012 Long-Term Performance Award. F11 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F11 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
Exercise / conversionMarket Share Units · Derivative | 8,801 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007238 · doc4.xml · derivative · entry 18 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,406 Underlying: Common Stock, $0.10 par value · 8,801 shares Expires 2016-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F4 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 6, 2012. The balance of the award is scheduled to vest in three equal installments on the second, third, and fourth anniversaries of the grant date. F4 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 6, 2012. The balance of the award is scheduled to vest in three equal installments on the second, third, and fourth anniversaries of the grant date. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
Exercise / conversionMarket Share Units · Derivative | 12,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007238 · doc4.xml · derivative · entry 17 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,491 Underlying: Common Stock, $0.10 par value · 12,062 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F2 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 2, 2010. The balance of the award is scheduled to vest on the fourth anniversary of the grant date. F3 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 1, 2011. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date. F10 · balance_after: Represents an aggregate of the derivative securities beneficially owned under the awards granted on March 2, 2010 and March 1, 2011. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
Exercise / conversionMarket Share Units · Derivative | 11,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007238 · doc4.xml · derivative · entry 16 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,553 Underlying: Common Stock, $0.10 par value · 11,715 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F3 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 1, 2011. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date. F3 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 1, 2011. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date. F10 · balance_after: Represents an aggregate of the derivative securities beneficially owned under the awards granted on March 2, 2010 and March 1, 2011. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
Tax withholdingCommon Stock, $0.10 par value | 51,754 | $37.53 | $1,942,327.62 |
DisclosureSEC source: 0001225208-13-007238 · doc4.xml · nonDerivative · entry 11 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,021 F7 · shares: Shares withheld for payment of taxes upon distribution of the 2010-2012 Long-Term Performance Award. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
Tax withholdingCommon Stock, $0.10 par value | 9,343 | $37.53 | $350,642.79 |
DisclosureSEC source: 0001225208-13-007238 · doc4.xml · nonDerivative · entry 10 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,775 F6 · shares: Shares withheld for payment of taxes upon vesting of market share units. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
Tax withholdingCommon Stock, $0.10 par value | 8,748 | $37.53 | $328,312.44 |
DisclosureSEC source: 0001225208-13-007238 · doc4.xml · nonDerivative · entry 9 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,118 F6 · shares: Shares withheld for payment of taxes upon vesting of market share units. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
Tax withholdingCommon Stock, $0.10 par value | 5,194 | $37.53 | $194,930.82 |
DisclosureSEC source: 0001225208-13-007238 · doc4.xml · nonDerivative · entry 8 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,866 F6 · shares: Shares withheld for payment of taxes upon vesting of market share units. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
OtherCommon Stock, $0.10 par value | 1,216 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007238 · doc4.xml · nonDerivative · entry 7 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,060 F5 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
OtherCommon Stock, $0.10 par value | 5,156 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007238 · doc4.xml · nonDerivative · entry 6 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,844 F5 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
OtherCommon Stock, $0.10 par value | 5,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007238 · doc4.xml · nonDerivative · entry 5 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,688 F5 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
Exercise / conversionCommon Stock, $0.10 par value | 8,801 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007238 · doc4.xml · nonDerivative · entry 4 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents vesting of one-quarter of market share units granted on March 6, 2012. The balance of the award is scheduled to vest in three equal installments on the second, third, and fourth anniversaries of the grant date. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
Exercise / conversionCommon Stock, $0.10 par value | 11,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007238 · doc4.xml · nonDerivative · entry 3 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,930 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents vesting of one-quarter of market share units granted on March 1, 2011. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
Exercise / conversionCommon Stock, $0.10 par value | 12,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007238 · doc4.xml · nonDerivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents vesting of one-quarter of market share units granted on March 2, 2010. The balance of the award is scheduled to vest on the fourth anniversary of the grant date. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
Exercise / conversionCommon Stock, $0.10 par value | 99,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007238 · doc4.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents distribution of performance shares earned under the 2010-2012 Long-Term Performance Award. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
Elicker John ESVP Pub Affairs & Inv Relation
|
OtherPerformance Shares · Derivative | 100.1076 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007239 · doc4.xml · derivative · entry 21 Elicker John E · CIK 0001554788 · SVP Pub Affairs & Inv Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,608.1076 Underlying: Common Stock, $0.10 par value · 100.1076 shares Expires 2015-03-31 F19 · derivative.exercise_price: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2015. F20 · shares: Represents dividend equivalents earned under the 2012-2014 Long-Term Performance Award. F19 · derivative.exercise_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2015. F19 · derivative.expiration_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2015. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
Elicker John ESVP Pub Affairs & Inv Relation
|
GrantPerformance Shares · Derivative | 2,508 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007239 · doc4.xml · derivative · entry 20 Elicker John E · CIK 0001554788 · SVP Pub Affairs & Inv Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,508 Underlying: Common Stock, $0.10 par value · 2,508 shares Expires 2015-03-31 F17 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2015. F18 · shares: Represents performance shares earned under the 2012-2014 Long-Term Performance Award. F17 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2015. F17 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2015. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
Elicker John ESVP Pub Affairs & Inv Relation
|
OtherPerformance Shares · Derivative | 246.3028 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007239 · doc4.xml · derivative · entry 19 Elicker John E · CIK 0001554788 · SVP Pub Affairs & Inv Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,457.2328 Underlying: Common Stock, $0.10 par value · 246.3028 shares Expires 2014-03-31 F15 · derivative.exercise_price: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2014. F16 · shares: Represents dividend equivalents earned under the 2011-2013 Long-Term Performance Award. F15 · derivative.exercise_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2014. F15 · derivative.expiration_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2014. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
Elicker John ESVP Pub Affairs & Inv Relation
|
GrantPerformance Shares · Derivative | 3,234 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007239 · doc4.xml · derivative · entry 18 Elicker John E · CIK 0001554788 · SVP Pub Affairs & Inv Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,210.93 Underlying: Common Stock, $0.10 par value · 3,234 shares Expires 2014-03-31 F13 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. F14 · shares: Represents performance shares earned under the 2011-2013 Long-Term Performance Award. F13 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. F13 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
Elicker John ESVP Pub Affairs & Inv Relation
|
Exercise / conversionPerformance Shares · Derivative | 11,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007239 · doc4.xml · derivative · entry 17 Elicker John E · CIK 0001554788 · SVP Pub Affairs & Inv Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 11,390 shares Expires 2013-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F1 · shares: Represents distribution of performance shares earned under the 2010-2012 Long-Term Performance Award. F9 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F9 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
Elicker John ESVP Pub Affairs & Inv Relation
|
OtherPerformance Shares · Derivative | 359.23 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007239 · doc4.xml · derivative · entry 16 Elicker John E · CIK 0001554788 · SVP Pub Affairs & Inv Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,390 Underlying: Common Stock, $0.10 par value · 359.23 shares Expires 2013-03-31 F11 · derivative.exercise_price: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2013. F12 · shares: Represents dividend equivalents earned under the 2010-2012 Long-Term Performance Award. F11 · derivative.exercise_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2013. F11 · derivative.expiration_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2013. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
Elicker John ESVP Pub Affairs & Inv Relation
|
GrantPerformance Shares · Derivative | 3,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007239 · doc4.xml · derivative · entry 15 Elicker John E · CIK 0001554788 · SVP Pub Affairs & Inv Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,030.77 Underlying: Common Stock, $0.10 par value · 3,310 shares Expires 2013-03-31 F9 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F10 · shares: Represents performance shares earned under the 2010-2012 Long-Term Performance Award. F9 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F9 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
Elicker John ESVP Pub Affairs & Inv Relation
|
Exercise / conversionMarket Share Units · Derivative | 1,043 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007239 · doc4.xml · derivative · entry 14 Elicker John E · CIK 0001554788 · SVP Pub Affairs & Inv Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,129 Underlying: Common Stock, $0.10 par value · 1,043 shares Expires 2016-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F4 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 6, 2012. The balance of the award is scheduled to vest in three equal installments on the second, third, and fourth anniversaries of the grant date. F4 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 6, 2012. The balance of the award is scheduled to vest in three equal installments on the second, third, and fourth anniversaries of the grant date. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
Elicker John ESVP Pub Affairs & Inv Relation
|
Exercise / conversionMarket Share Units · Derivative | 1,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007239 · doc4.xml · derivative · entry 13 Elicker John E · CIK 0001554788 · SVP Pub Affairs & Inv Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,377 Underlying: Common Stock, $0.10 par value · 1,376 shares Expires 2014-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F2 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 2, 2010. The balance of the award is scheduled to vest on the fourth anniversary of the grant date. F3 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 1, 2011. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
Elicker John ESVP Pub Affairs & Inv Relation
|
Exercise / conversionMarket Share Units · Derivative | 1,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007239 · doc4.xml · derivative · entry 12 Elicker John E · CIK 0001554788 · SVP Pub Affairs & Inv Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,720 Underlying: Common Stock, $0.10 par value · 1,360 shares Expires 2015-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F3 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 1, 2011. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date. F3 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 1, 2011. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:50 UTC |
Elicker John ESVP Pub Affairs & Inv Relation
|
Tax withholdingCommon Stock, $0.10 par value | 3,467 | $37.53 | $130,116.51 |
DisclosureSEC source: 0001225208-13-007239 · doc4.xml · nonDerivative · entry 11 Elicker John E · CIK 0001554788 · SVP Pub Affairs & Inv Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,135.97 F7 · shares: Shares withheld for payment of taxes upon distribution of the 2010-2012 Long-Term Performance Award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.